Valneva SE (VALN) is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Headquartered in Saint-Herblain (France), Valneva centralizes all its activities in one place, with integrated research laboratories, manufacturing and commercial functions. With over two decades of experience in vaccine development, it is dedicated to improve the quality of life by empowering everyone to live healthily, without fear of infectious diseases.
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® for the prevention of Japanese encephalitis, a flu-like syndrome that can cause paralysis, seizures, and death; and DUKORAL® for cholera and, in some countries, prevention of diarrhea caused by ETEC. In addition, Valneva has various vaccines in development, including candidates for Lyme disease, chikungunya, Zika and the SARS-CoV-2 virus. Furthermore, Valneva has a unique end-to-end capability to develop, manufacture and commercialize vaccines, providing a distinguishing competitive advantage.
Valneva’s Lyme disease vaccine candidate, VLA15, is the only active vaccine program in clinical development against Lyme disease, a severe and growing threat to public health. The vaccine is expected to raise awareness about this ubiquitous disease and serve as a preventive measure for people at high risk.
Another key project is their collaboration with UK government for the development of VLA2001. This could possibly be the first inactivated SARS-CoV-2 vaccine developed in Europe. As the world combats the COVID-19 pandemic, Valneva continues to use its expertise in vaccine development and manufacturing to help tackle this global public health crisis.
Valneva operates through broad alliances with some of the largest pharmaceutical companies, including a license agreement with Chemo-Sero-Therapeutic Research Institute (Kaketsuken) for IXIARO/JESPECT and a marketing and distribution agreement with PaxVax for the distribution of DUKORAL and VIVOTIF outside Europe and North America.
With the commitment towards global health and a unique business model that focuses on diseases overlooked by major manufacturers, Valneva is leading the way in creating solutions for those who need it the most. It combines the entrepreneurial spirit of a biotech firm with the industry know-how of a big pharma company, making them a standout in the world of vaccine development.